Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Metabolic Enzyme Considerations In Cancer Therapy.

Jain, Amit E. and Jain, Sweta and Rana, A.C. (2007) Metabolic Enzyme Considerations In Cancer Therapy. Malaysian Journal of Medical Sciences, 14 (1). pp. 10-17. ISSN 1394195X

Full text not available from this repository.

Official URL: http://www.medic.usm.my/publication/mjms/

Affiliations

B.R. Nahata College of Pharmacy, India
B.N. College of Pharmacy, India

Abstract

The clinical application of new antineoplastic drugs has been limited because of low therapeutic index and lack of efficacy in humans. Thus, improvement in efficacy of old and new anticancer drugs has been attempted by manipulating their pharmacokinetic properties. Four inter-related factors, which determine the pharmacokinetic behavior of a drug include absorption, distribution, metabolism and excretion. The drug-metabolizing enzymes have been classified in two major groups: phase I and phase II enzymes. Phase I enzymes comprise the oxidases,
dehydrogenases, deaminases, hydrolases. Phase II enzymes include primarily UDPglucuronosyltransferases (UGTs), glutathionetransferases (GSTs), sulfotransferases (SULTs), N-acetyl transferases (NATs), methyltransferases and aminoacid transferases that conjugate products of phase I reactions and parent compounds with appropriate functional groups to generate more water soluble compounds which are more readily eliminated. The importance of these enzymes in the metabolism of specific drugs varies according to the chemical nature of the drug, Drug metabolism is modulated by factors that change among species and even
among individuals in a population. Such factors can be environmental or genetic in origin, and influence how a drug is metabolized and to what extent. An awareness
of these variables is invaluable when the safety and efficacy of new anticancer drugs are evaluated.

Item Type:Journal
Keywords:Cancer, metabolic enzyme consideration, UDP glucuronosyltransferases, glutathionetransferases, sulfotransferases, N-acetyl transferases
Subjects:R Medicine
ID Code:637

1. Buonarati M, Felton J, Carcinogenesis 1990; 11: 1133-1138.

2. Wrighton S, Schuetz E, Thummel, K, Shen, D, Korzekwa, K, Watkins, P.B, Drug Metab Rev 2000;32: 339-361.

3. Lin J, Cashman J, Chem Res Toxicol 1997; 10: 842-852.

4. Pan S, Bachur N, Mol Pharmacol 1980; 17: 95-99.

5. Keuzenkamp-Jansen, C, DeAbreu R, Bokkerink J, Lambooy M, Trijbels J J Pediatr Hematol Oncol 1996, 18: 145-150.

6. Ross D, Quinone Reductases Guengerich F.P, 3rd Edn, New York, Pergamon. Comprehensive Toxicology 1997; 179-198.

7. Tomasz C.M, Olson J, Chatterjie N, Biochemistry, 1974; 13: 4878-4887.

8. Sladek N, Curr Pharm Des 1999; 5: 607-625.

9. Diasio R, Harris B, Clin Pharmacokinet 1989; 16: 215-237.

10. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M, Br J Clin Pharmacol 1992; 34: 130-138.

11. Wasserman E, Myara A, Lokiec F, Goldwasse F, Trivin F, Mahjoubi M, Misset J.L, Cvitkovic E, Ann Oncol 1997; 8: 1049-1051.

12. Weinshilboum R.M, Otterness D.M, Aksoy I.A, Wood T.C, Her C, Raftogianis R.B, FASEB J 1997; 11: 3-14.

13. Windmill K, Gaedigk A, Hall P, Samaratunga H, Grant D, McManus M, Toxicol Sci 2000; 54: 19-29.

14. van Iersel, M., van Lipzig, M, Rietjens I, Vervourt J,

Van Bladeren, P, FEBS Lett 1998; 441:153-157.

15. Tew K, Bomber A, Hoffman S, Cancer Res 1988; 48: 3622-3625.

16. Ball L, Rater J, Gustafsson J, Gustafsson B, Kohan M, Lewtas J, Carcinogenesis 1991; 12: 1-5.

17. Coughtrie M.W.H, Dajani R, Kauffman F.C, Rubin G.L, Sharp S. Drug Metabolism: Towards the next millennium, IOS Press 1998; 89-100.

18. Fretland A, Omiecinski C, Chem Biol Interact 2000;

129: 41-59.

19. Satoh T, Hosokawa M, Annu Rev Pharmacol Toxicol

1998; 38: 257-288.

20. Peters G, Schornagel J, Milano G, Cancer Surveys, Workman P. and Graham M.A. Ed. Cold Spring Harbor

Laboratory Press, New York 1993; 17: 123-156.

21. Storniola A, Allerheiligen S, Pearce H, Semin Oncol,

1997; 24: s7-2-s7-7.

22. Elford H, Van’t Ried B, Pharmac Ther 1985; 29: 239-254.

23. Lind M J, Ardiet C, Cancer Surveys, Workman, P. and

Graham, M. A., Ed. Cold Spring Harbor Laboratory Press, New York 1993; 17: 157-188.

24. Ross D, Kepa J, Winski S, Beall H, Anwar A, Siegel

D, Chem Biol Interact 2000; 129: 77-97.

25. Kestell P, Pruijn P, Siim B, Palmer B, Wilson W, Cancer

Chemother Pharmacol 2000; 46: 365-374.

26. Graham M.A, Riley R.J, Ker D.J, Pharma Ther 1991,

51: 275-289.

27. Master J, Hepburn P, Walker L, Highman W, Trejdosiewicz L, Povey S, Parker M, Hill B, Riddle P,

Franks L M, Cancer Res 1986; 46: 3630-3636.

28. Kuramochi H, Motegi A, Takeuchi T, J Antibiot (Tokyo) 1988; 41: 1846-1853

29. Mahdadi R, Kenani A, Pommery N, Pommery J, Henichart J P, Lhermitte, M., Cancer Chemother Pharmacol 1991;28:22-26.

30. Jimeno J, Faircloth G, Cameron L, Drugs Future, 1996;

21: 1155.

31. Mcleod, H.L, Evans, W.E, Cancer Surveys; W.P, Graham, M.A Ed. Cold Spring Harbor Ltory Press, New York, 1993; 17: 253-268.

32. Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A,

Bombardelli E, Mancuso S, Ojima I, Scambia G, Br J. Cancer 2000; 83: 1762-1768.

33. Prakash V, Timasheff S N, Biochemistry 1985; 24: 5004-5010.

34. Lonning P, Lien E, Pharmacokinetics and Cancer Chemotherapy, volume 17 ed.; Workman P, Graham M A, eds; Cold Spring Harbor Laboratory Press: 1993,pp. 343-370.

35. Saijo N, Ann N Y Acad Sci 2000; 922:92-99.

36. Mauro M.J, Druker B. J Curr Opin Oncol 2001;13:3-7.

37. Carlson B.A, Dubay M.M, Sausville E.A, Brizuela L,

Worland P.J, Cancer Res 1996; 56: 2973-2978

38. Griffioen A W, Molema G, Pharmacol Rev 2000; 52:237-268.

39. Eriksson T, Roth B, Fyge A, Hoglund P, Chirality, 1995;

7: 44-52.

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.